



## Advances in Adenoid Cystic Carcinoma Translational Research

Boston, MA,  
June 15-16, 2023

### **Thursday – June 15, 2023**

7:00-8:00AM Continental Breakfast  
8:00-8:10AM **Welcome and Introduction – Jeff and Marnie Kaufman**

### **ACC Model Development**

8:10-8:20AM Moderator: Carlos Caulin, PhD, University of Arizona Cancer Center  
8:20-8:45AM Patrick Ha, MD, University of California, San Francisco – Inducible Myb/MYB-NFIB Cell Models: A Work in Progress  
8:45-9:10AM Tessa DesRoches, PhD, Kiyatec – Ex Vivo Models for Drug Response Assessment  
9:10-9:35AM Evgeny Izumchenko, PhD, University of Chicago – Integration of Public Genomic Data in Secondary Analysis – What is Available for ACC (*virtual*)  
9:35-9:50AM Panel Discussion  
**9:50-10:00AM Break**

### **ACC Characterization**

10:00-10:10AM Moderator: Rogerio Castilho, DDS, MS, PhD, University of Michigan  
10:10-10:35AM Mattias Andersson, DMD, PhD, University of Gothenburg – Clinical and Molecular Significance of MYB and 1p/6q Rearrangements in Adenoid Cystic Carcinoma (*virtual*)  
10:35-11:00AM Scott Ness, PhD, University of New Mexico – Complexities of Adenoid Cystic Carcinoma Revealed by RNA-Seq Analyses  
11:00-11:25AM Piero Dalerba, MD, Columbia- Differential Purification, Dynamic Reconstitution and Selective Pharmacological Targeting of Ductal and Myoepithelial Lineages in Human Adenoid Cystic Carcinomas (ACCs)  
11:25-11:50AM Alex Pearson, MD, PhD, University of Chicago- Deep Neural Network Analysis of ACC  
11:50-12:05PM Panel Discussion  
**12:05-1:30PM Lunch and Poster Viewing**

### **Targeting MYB**

1:30-1:40PM Moderator: Sara Buhrlage, PhD, Dana-Farber Cancer Institute  
1:40-2:05PM Chris Yates, MS, Rgenta Therapeutics – Unlocking the Therapeutic Potential of MYB through Novel RNA Targeting Mechanisms

- 2:05-2:30PM Max Pimkin, MD, PhD, Dana-Farber Cancer Institute – A Fast-Kinetics Approach to the Function and Pharmacologic Targeting of MYB
- 2:30-2:55PM Charles Kung, PhD, Remix Therapeutics – Reprogramming RNA: Targeting MYB in Adenoid Cystic Carcinoma
- 2:55-3:20PM Rob Ramsay, PhD, Peter MacCallum Cancer Centre – MYPHISMO – Preliminary Observations for a Self-Antigen (MYB) Vaccine - Safety and Signal Finding in Immunologically Inert Adenoid Cystic Carcinoma
- 3:20-3:35PM Panel Discussion
- 3:35-3:45PM Break**

### Targeting the ACC Surfaceome

- 3:45-3:55PM Moderator: Nikki Spardy Burr, PhD, ACCRF
- 3:55-4:20PM Daniel McGrail, PhD, Cleveland Clinic – Prognostic and Therapeutic Implications of ACC Molecular Subtypes
- 4:20-4:45PM Hyu Kang, MD, MPH, FACP, University of California, San Francisco – Targeting AXL through an Antibody-Drug Conjugate in ACC
- 4:45-5:00PM Panel Discussion
- 6:30-9:00PM Dinner at Basile Restaurant (162 Columbus Avenue)**

### Friday - June 16, 2023

- 7:00-8:00AM Continental Breakfast

### Clinical Trial Developments and Design

- 8:30-8:40AM Moderator: Hyu Kang, MD, MPH, FACP, University of California, San Francisco
- 8:40-9:05AM Alan Ho, MD, PhD, Memorial Sloan Kettering Cancer Center – Immunotherapy in ACC: Challenges and Lessons Learned (*virtual*)
- 9:05-9:30AM Renata Ferrarotto, MD, MD Anderson Cancer Center – Natural History of Lung Metastasis and Prognostic Value of Time to Progression and Lung Metastasis Volume Doubling Time in Patients with Adenoid Cystic Carcinoma (*virtual*)
- 9:30-9:55AM William Boyle, PhD, BioAtla – Conditionally Active Biologics: A New Frontier for ADC's
- 9:55-10:20AM Glenn Hanna, MD, Dana-Farber Cancer Institute – Phase 1 Trial Results for the Pan-NOTCH Inhibitor CB-103 for Patients with Advanced ACC and Identifying Future Therapeutic Targets
- 10:20-10:35AM Panel Discussion
- 10:35-10:45AM Break**
- 10:45-11:15AM ACCRF – Round table discussion: Clinical Trial Design for Recurrent/Metastatic ACC
- 11:15-11:45PM Paul Swiecicki, MD, University of Michigan – Clinical Trial Concept: Cytotoxic Chemotherapy in Recurrent/Metastatic ACC
- 11:45-11:55AM Closing Remarks – Jeff and Marnie Kaufman**
- 11:55-1:00PM Lunch, Final Poster Review and Send off**